Publication
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.
Lorenzo Falchi, Joost S P Vermaat, Joshua D Brody, Lori Leslie, Fritz Offner, Jacob Haaber Christensen, Marcel Nijland, David Belada, Björn Engelbrekt Wahlin, Kristina Drott, Pilar Gomez Prieto, Kateřina Kopečkova, Alejandro Martín García-Sancho, Jian P Mei, Işıl Altıntaş, Malene Risum, Aidan Reilly, Jun Zou, Pau Abrisqueta
- Source
- PubMed
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260917-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Chemotherapy-free regimens, such as rituximab and lenalidomide, are attractive first-line treatment options for follicular lymphoma, but combinations providing deeper, more durable responses are needed. We aimed to assess 3-year activity and safety of epcoritamab, a subcutaneously…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04663347registry_reference1.00
Candidate 1
- cancerNon-Hodgkin Lymphomadictionary0.60
Registered trialsNCT04663347
Curated evidence
Evidence citing this paper (0)
Data not yet available